Clinical Evidence Behind Mounjaro vs Wegovy Weight Loss
Weight Loss Results: Mounjaro vs Wegovy Dose Equivalent Evidence
When evaluating Mounjaro vs Wegovy dose equivalent results, it's essential to examine the published clinical trial data for each treatment. The STEP programme demonstrated that patients taking Wegovy alongside diet and exercise achieved ~15% average weight loss at 68 weeks in the pivotal STEP 1 trial. Mounjaro's SURMOUNT trials showed impressive results with their dual-receptor approach, though direct head-to-head comparisons aren't possible due to different trial designs and patient populations. Both treatments represent significant advances in prescription weight management, with each offering unique mechanisms that may suit different patients.
The key difference lies in their pharmacological approach: Wegovy targets GLP-1 receptors exclusively, whilst Mounjaro activates both GIP and GLP-1 receptors as a dual agonist. This distinction affects how each treatment influences appetite regulation and glucose metabolism. Your prescriber can help determine which mechanism may be more appropriate based on your individual health profile and weight management goals.
Wegovy Pricing Structure and Mounjaro vs Wegovy Cost Comparison
Understanding the financial commitment for Mounjaro vs Wegovy dose equivalent treatments helps with treatment planning. Wegovy follows a structured dose escalation: 0.25mg starter dose (£79.99), progressing to 0.5mg (£94.99), 1mg (£99.99), 1.7mg (£139.99), and maintenance 2.4mg (£209.99). Our bundle options provide convenience for multiple months' supply, such as the Intro Trio containing 0.25mg, 0.5mg, and 1mg doses for £299.99. New customers can apply code FIRST40 at checkout, whilst returning customers use DOSE25 to reach these final prices.
Mounjaro pricing follows a different structure due to its unique dosing schedule, but both treatments are available through our streamlined ordering process. The convenience of our bundles extends beyond potential savings - they ensure treatment continuity and reduce the need for multiple orders. This is particularly valuable during the initial dose escalation phase when consistent supply is crucial for optimal results.
STEP Trial Results: Wegovy's Clinical Evidence Base
The Wegovy clinical programme, particularly the landmark STEP trials published by Wilding et al. in NEJM 2021, provides robust evidence for weight loss efficacy. STEP 1 demonstrated ~15% average weight loss at 68 weeks, whilst STEP 3 combined with intensive behavioural therapy achieved ~16% weight reduction. The two-year STEP 5 data showed sustained ~clinically studied weight loss, indicating long-term effectiveness when treatment continues.
Perhaps most significantly, the SELECT cardiovascular outcomes trial demonstrated a 20% reduction in major cardiovascular events (hazard ratio 0.80). These results position Wegovy not just as a weight management tool, but as a treatment with broader health implications. All these outcomes occurred when Wegovy was used alongside a reduced-calorie diet and increased physical activity, emphasising the importance of comprehensive lifestyle modification.
How Wegovy Works: GLP-1 Mechanism in Mounjaro vs Wegovy Comparison
Wegovy functions as a GLP-1 receptor agonist, mimicking the action of glucagon-like peptide-1, a natural hormone that regulates appetite and blood glucose. When administered via the once-weekly FlexTouch pen, semaglutide binds to GLP-1 receptors in the brain's appetite control centres, promoting satiety and reducing food cravings. This mechanism slows gastric emptying, meaning you feel fuller for longer after eating smaller portions. The treatment also influences reward pathways in the brain that govern food-seeking behaviour, potentially reducing cravings for high-calorie foods. Unlike Mounjaro's dual-receptor approach, Wegovy's focused GLP-1 action has been extensively studied across multiple patient populations, providing a well-characterised safety and efficacy profile. This single-pathway mechanism may offer advantages for patients who prefer treatments with well-established pharmacological profiles backed by extensive clinical data.
EverydayMeds Ordering Process for Mounjaro vs Wegovy Selection
Our streamlined process accommodates both Mounjaro and Wegovy prescribing through a comprehensive 3-minute online clinical assessment. This assessment captures your medical history, current medications, weight management goals, and any contraindications that might influence treatment choice. Following submission, our qualified prescribers review your assessment within 3 working days (or 24 hours with express service) to determine suitability and recommend the most appropriate treatment. Once approved, your prescription is dispensed from our GPhC-registered pharmacy (#9012878) and dispatched via next-day cold-chain delivery to maintain product integrity. The entire process maintains clinical governance whilst providing the convenience of online access to prescription weight management treatments.
Storage and Practical Considerations: Wegovy vs Mounjaro Logistics
Storage requirements represent a practical difference in the Mounjaro vs Wegovy dose equivalent comparison, particularly for patients who travel frequently. Wegovy offers superior storage flexibility, remaining stable for up to 6 weeks at room temperature (below 30°C) once removed from refrigeration, compared to Mounjaro's 21-day room temperature limit. Both treatments require refrigerated storage at 2-8°C before first use and utilise convenient pre-filled pen injectors. Wegovy's FlexTouch pen system provides dose accuracy and ease of use, with clear dosing windows and audible click confirmation. The mandatory dose escalation schedule means you cannot skip doses - this graduated approach minimises gastrointestinal side effects whilst optimising therapeutic response. The extended room temperature stability makes Wegovy particularly suitable for business travellers or those with irregular schedules.
UK-Specific Wegovy Access and Mounjaro Alternative Considerations
The UK regulatory landscape for Mounjaro vs Wegovy dose equivalent treatments reflects their different approval pathways and clinical evidence bases. Wegovy received NICE recommendation (TA875) with specialist weight management support, whilst Mounjaro's UK availability follows its own regulatory timeline. This creates practical implications for NHS availability, private prescription access, and insurance coverage considerations. EverydayMeds provides private prescription access to both treatments, ensuring patients aren't limited by NHS waiting lists or availability constraints.
Regional prescribing patterns across the UK show growing familiarity with GLP-1-based treatments among healthcare providers, though individual prescriber experience may vary between the two medications. Our clinical team's expertise with both treatments ensures appropriate selection regardless of your location or previous treatment history. This UK-focused approach recognises the unique healthcare landscape and regulatory requirements that British patients navigate when accessing advanced weight management treatments.
Making Your Mounjaro vs Wegovy Dose Equivalent Decision
Choosing between Mounjaro and Wegovy requires careful consideration of clinical evidence, practical factors, and individual health circumstances. Both treatments are available from EverydayMeds, and your prescriber can help determine which option aligns best with your weight management goals and medical history. Consider factors such as your travel requirements (favouring Wegovy's extended room temperature stability), tolerance for different side effect profiles, and preference for single versus dual-receptor mechanisms. The robust clinical evidence supporting both treatments means your decision can focus on practical and personal factors rather than concerns about efficacy.
Schedule your clinical assessment today using discount code FIRST40 for new customers or DOSE25 for returning patients. Our expert prescribers will guide you through the Mounjaro vs Wegovy selection process, ensuring you receive the most appropriate treatment for your individual circumstances. Visit https://everydaymeds.co.uk/collections/wegovy to begin your weight management journey with confidence in clinical expertise and regulatory compliance.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
